Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
HOUSTON, July 10, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the completion of its End of...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
- 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations - Current median durability of response (mDOR) of CRc's = 6 months and increasing (n=9) - In 2nd line subjects (n=10) Annamycin in combination with Cytarabine (AnnAraC) achieved an...
Moleculin to Present at the Virtual Investor Pitch Conference
Live video webcast on Tuesday, June 18th at 3:00 PM ET HOUSTON, June 12, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors...
Moleculin to Participate in the Virtual Investor Lunch Break Series
Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Wednesday, June 12th at 12:00 PM ET HOUSTON, June 5, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of...
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
HOUSTON, May 16, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced its abstract has been...
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
- Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin - Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models...
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) - Also announced MB-106 reaches 20 subjects enrolled - Company to...
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
Patent, once issued, will provide composition protection through 2040, with potential for additional term extension Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an accelerated approval pathway HOUSTON, May 9, 2024 -- Moleculin Biotech,...
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
HOUSTON, May 8, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its...
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13)Full MB-106 trial reaches 20 subjects with CRc of 45% in 1st - 7th line, with median durability at 4.9 months and climbingInterim data supports...